Affordable Access

deepdyve-link
Publisher Website

Formulation and in vitro evaluation of upconversion nanoparticle-loaded liposomes for brain cancer.

Authors
  • Narendra,1
  • Mehata, Abhishesh Kumar1
  • Viswanadh, Matte Kasi1
  • Sonkar, Roshan1
  • Pawde, Datta Maroti1
  • Priya, Vishnu1
  • Singh, Mamata2
  • Koch, Biplob2
  • S Muthu, Madaswamy1
  • 1 Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (BHU), Varanasi 221005, India. , (India)
  • 2 Department of Zoology, Genotoxicology & Cancer Biology Lab, Institute of Science, Banaras Hindu University, Varanasi 221005, India. , (India)
Type
Published Article
Journal
Therapeutic Delivery
Publisher
"Future Science, LTD"
Publication Date
Sep 01, 2020
Identifiers
DOI: 10.4155/tde-2020-0070
PMID: 32867624
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Aim: This work focused on the development of transferrin-conjugated theranostic liposomes consisting of docetaxel (DXL) and upconversion nanoparticles for the diagnosis and treatment of gliomas. Materials & methods: Upconversion nanoparticles and docetaxel-loaded theranostic liposomes were prepared by a solvent injection method. Formulations were analyzed for physicochemical properties, encapsulation efficiency, drug release, elemental analysis, cytotoxicity and fluorescence. Results: The particle size was around 200 nm with spherical morphology and an encapsulation efficiency of up to 75.93%, was achieved for liposomes with an in vitro drug release of 71.10%. The IC50 values demonstrated enhanced cytotoxicity on C6 glioma cells with targeted liposomes in comparison with nontargeted liposomes. Conclusion: Prepared theranostic liposomes may be promising for clinical validation after an in vitro and in vivo evaluation on cell lines and animals, respectively.

Report this publication

Statistics

Seen <100 times